Response to: 'Can we further SPARkle the SPAR model?' by Kavadichanda et al

Wanlong Wu^{1

2}, Suzana Jordan¹, Oliver Distler¹

Affiliations

¹ Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
² Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Comment

Wanlong Wu et al. Ann Rheum Dis. 2019 Sep.

. 2019 Sep;78(9):e94.

doi: 10.1136/annrheumdis-2018-213962. Epub 2018 Jul 21.

Wanlong Wu^{1

2}, Suzana Jordan¹, Oliver Distler¹

¹ Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
² Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

No abstract available

Keywords: methotrexate; systemic sclerosis; treatment.

Conflict of interest statement

Competing interests: None declared.

Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim H, Ye S, Siegert E, Allanore Y, Hoffmann-Vold AM, Distler O. Wu W, et al. Ann Rheum Dis. 2018 Sep;77(9):1326-1332. doi: 10.1136/annrheumdis-2018-213201. Epub 2018 Jun 6. Ann Rheum Dis. 2018. PMID: 29875097
Can we further SPARkle the SPAR model?
Kavadichanda CG, Negi VS. Kavadichanda CG, et al. Ann Rheum Dis. 2019 Sep;78(9):e93. doi: 10.1136/annrheumdis-2018-213954. Epub 2018 Jun 29. Ann Rheum Dis. 2019. PMID: 29959182 No abstract available.